Samsara BioCapital LLC bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,217,146 shares of the company's stock, valued at approximately $36,450,000. Upstream Bio accounts for 4.9% of Samsara BioCapital LLC's investment portfolio, making the stock its 6th biggest position. Samsara BioCapital LLC owned about 4.14% of Upstream Bio at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in UPB. US Bancorp DE bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $27,000. Legal & General Group Plc acquired a new position in Upstream Bio in the fourth quarter worth about $28,000. Summit Investment Advisors Inc. acquired a new stake in Upstream Bio during the fourth quarter valued at approximately $30,000. Tower Research Capital LLC TRC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. acquired a new position in shares of Upstream Bio in the 4th quarter worth approximately $142,000.
Upstream Bio Stock Down 1.9 %
Shares of UPB traded down $0.17 during trading hours on Monday, hitting $8.48. The stock had a trading volume of 303,640 shares, compared to its average volume of 266,849. The company's fifty day moving average is $7.96 and its two-hundred day moving average is $14.00. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
